SCHEMBL6093369

SCHEMBL6093369

N#Cc1ccc(OC[C@H](O)CN2CC3CN(CC4CC4)CC3C2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
SIGMAR1 Q99720 1/20 0.54
KCNH2 Q12809 1/20 0.51
ATM Q13315 1/20 0.47
AGER Q15109 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
GLA P06280 1/20 0.45
USP2 O75604 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
HRH1 P35367 1/20 0.45
CCR3 P51677 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093365 1.00 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL7033210 0.92 KDM4E (0.53) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL2968351 0.91 KCNH2 (0.62) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL6992466 0.87 KDM4E (0.51) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL6094323 0.85 SIGMAR1 (0.54) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL6094329 0.85 SIGMAR1 (0.54) KDM4EALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL6095179 0.84 MEN1 (0.56) KDM4EALDH1A1MEN1KMT2AKCNH2
SCHEMBL6095326 0.82 MEN1 (0.50) KDM4EALDH1A1MEN1KMT2AKCNH2
SCHEMBL5965631 0.82 KDM4E (0.58) KDM4EALDH1A1MEN1KMT2AKCNH2
SCHEMBL6095749 0.82 HRH2 (0.59) KDM4EALDH1A1MEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144914-B2 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-12-05 US disclosed
EP-1360187-B1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-03-18 US disclosed
EP-1360187-A1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-11-12 EP disclosed
WO-2002060902-A1 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, CACNA1E KDM4E 3426/4885ALDH1A1 214/4885MEN1 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.